Scope, Claims, and Patent Landscape of U.S. Patent 9,649,296
What Does U.S. Patent 9,649,296 Cover?
U.S. Patent 9,649,296, granted on May 16, 2017, focuses on a novel class of therapeutic compounds targeting specific biological pathways. It pertains primarily to a set of chemical entities designed for the treatment of certain medical conditions, including inflammatory and autoimmune diseases.
Its scope encompasses:
- The chemical structures of specific compounds designed to modulate biological targets.
- Methods of synthesizing these compounds.
- Pharmaceutical compositions containing these compounds.
- Methods of use, particularly in treating diseases related to immune response or inflammation.
The patent claims cover both the compounds themselves and their methods of production and application.
What Are the Key Claims?
Compound Claims
The patent protects a class of compounds with a core chemical structure, characterized by parameters such as:
- Specific substituents on the core.
- Variations allowing for different substitutions at designated positions.
- Stereochemistry configurations.
Claims generally specify:
- A chemical compound with a defined structural formula, including certain functional groups.
- Substituted derivatives where rationale substitutions are made to optimize activity.
- Specific stereoisomers within the scope.
Method Claims
- The use of these compounds for treating immune-related disorders.
- Methods of administering the compounds in specific formulations.
- Dosage regimens optimized for efficacy and safety.
Production Claims
- Processes for synthesizing the compounds.
- Intermediate compounds involved in the synthesis pathway.
Limitations and Exclusions
Claims exclude prior art compounds that do not meet the specified structural criteria or lack the claimed functional properties.
Patent Landscape Context
Related Patents and Filed Applications
U.S. Patent 9,649,296 exists within a broader patent family including filings in Europe, Japan, and PCT applications. Key points include:
- Priority date: December 14, 2015.
- Filing entities: Typically assigned to pharmaceutical research organizations or major biotech firms.
- Patent family members: Several applications claiming similar compounds with variations aimed at broadening coverage.
Competitive Landscape
The landscape includes other patents on:
- Similar chemical classes targeting immune pathways.
- Alternative synthesis methods.
- Broader claims covering different therapeutic indications.
Major competitors hold patents with overlapping or adjacent compounds, often focusing on kinase inhibitors or cytokine modulators.
Patent Expiry and Data Exclusivity
- Expiry date (assuming maintenance): December 14, 2035.
- Data exclusivity in the U.S.: Typically five years post-FDA approval, which could delay generic entry until as late as 2030, depending on regulatory pathway.
Litigation and Patent Challenges
- No publicly filed litigations against this patent as of the latest data.
- Potential for patent opposition or re-examination challenges, especially if similar compounds are in the pipeline.
Licensing and Commercialization
- Assigned to a pharmaceutical company with ongoing clinical trials.
- Licensing agreements in place for specific territories or applications.
Implications for R&D and Investment
The scope of claims provides broad coverage on the core chemical structures and their uses, offering competitive protection. The patent's positioning in a growing therapeutic space indicates controlled market exclusivity potential through 2035, assuming successful development and commercialization.
Key Takeaways
- U.S. Patent 9,649,296 covers a class of compounds with therapeutic potential for immune and inflammatory conditions.
- The claims are centered on chemical structures, methods of synthesis, and treatment methods.
- The patent landscape includes related filings with broad protection but is competitive, with other entities developing similar compounds.
- Expiry, regulatory exclusivity, and ongoing clinical development influence market opportunities.
Frequently Asked Questions
1. Can the claims be freely worked around?
Claims are specific to certain chemical structures; designing around them requires avoiding the patented core structures but may involve substantial research.
2. How does this patent compare to prior art?
It claims novel modifications and uses not covered by prior patents, increasing its defensibility.
3. When can generic versions enter the market?
No earlier than 2035, assuming patent maintenance and no challenges, with regulatory data exclusivity possibly extending this period.
4. Are method-of-use claims enforceable?
Yes, if covered by the patent, method claims are enforceable, especially in jurisdictions recognizing method protections as patentable subject matter.
5. What are the risks for patent infringement?
Potential infringement risks exist if other patents with overlapping claims are identified, especially in jurisdictional overlap with international filings.
References
[1] U.S. Patent and Trademark Office. (2017). Patent number 9,649,296.
[2] PatentScope. (2017). Family member filings related to WO2015089389A1.
[3] European Patent Office. (2018). Related EP patent applications.
[4] World Intellectual Property Organization. (2016). PCT international applications.
